Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma

Trial Profile

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 28 Jul 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top